MRNA logo

Moderna, Inc.

MRNA
Healthcare|Biotechnology|US
$254.19
+12.73 (+5.27%)
Tangible Book / Share
$17.05
Cash / Share
$12.90

Financials

Financial Snapshot

Market Cap
$101.48B
Enterprise Value
$104.47B
Revenue (TTM)
$2.52B
Net Income (TTM)
-$2.79B
Cash & Investments
$5.17B
Net Cash
$992.0M
Free Cash Flow (TTM)
-$1.95B
Operating CF (TTM)
-$1.76B
Debt/Equity
0.61

Cash Runway & Burn Rate

Cash on Hand
$5.17B
Quarterly Burn
$441.0M
Monthly Burn
$147.0M
Est. Runway
~11.7 quarters
MetricTrend2016201720182019202020212022202320242025TTM
Cash & Investments
$1.06B$756.0M$1.52B$1.10B$4.61B$10.73B$9.90B$8.60B$7.03B$5.80B$5.17B
Operating Cash Flow
$66.7M-$331.5M-$330.9M-$459.0M$2.03B$13.62B$4.98B-$3.12B-$3.00B-$1.87B-$1.76B
Free Cash Flow
$33.6M-$389.9M-$436.6M-$490.5M$1.96B$13.34B$4.58B-$3.83B-$4.05B-$2.06B-$1.95B
Capital Expenditure
-$33.1M-$58.4M-$105.8M-$31.6M-$67.4M-$284.0M-$400.0M-$707.0M-$1.05B-$192.0M-$185.0M
Financing Cash Flow
$472.9M$168.0K$1.23B$51.1M$2.03B-$873.0M-$3.45B-$1.38B$56.0M$593.0M$3.34B

R&D Spending

R&D (TTM)
$2.66B
R&D Intensity
105.3%
R&D Growth vs Prior
-15.1%
MetricTrend2016201720182019202020212022202320242025TTM
Revenue
$108.4M$205.8M$135.1M$60.2M$803.4M$17.74B$18.88B$6.85B$3.20B$1.94B$2.52B
R&D Expense
$274.7M$410.5M$454.1M$496.3M$1.37B$1.99B$3.29B$4.84B$4.54B$3.13B$2.66B
R&D % of Revenue
253.4%199.4%336.2%824.3%170.6%11.2%17.5%70.8%142.0%161.1%105.3%
SG&A
$57.5M$64.7M$94.3M$109.6M$188.3M$567.0M$1.13B$1.55B$1.17B$1.02B$979.0M

Income Statement

MetricTrend2016201720182019202020212022202320242025TTM
Revenue
$108.4M$205.8M$135.1M$60.2M$803.4M$17.74B$18.88B$6.85B$3.20B$1.94B$2.52B
Cost of Revenue
$15.1M$20.5M$24.9M$31.0M$39.2M$2.62B$5.42B$4.69B$1.46B$868.0M$1.82B
Gross Profit
$93.3M$185.3M$110.2M$29.2M$764.2M$15.12B$13.46B$2.15B$1.74B$1.08B$707.0M
R&D
$274.7M$410.5M$454.1M$496.3M$1.37B$1.99B$3.29B$4.84B$4.54B$3.13B$2.66B
SG&A
$57.5M$64.7M$94.3M$109.6M$188.3M$567.0M$1.13B$1.55B$1.17B$1.02B$979.0M
Operating Income
-$223.8M-$269.4M-$468.9M-$545.7M-$763.1M$13.30B$9.42B-$4.24B-$3.94B-$3.07B-$2.93B
Interest Expense
$0.00$132.0K$3.1M$6.6M$9.9M$18.0M$29.0M$38.0M$24.0M$10.0M$25.0M
Pretax Income
-$215.2M-$256.0M-$440.0M-$514.7M-$744.5M$13.29B$9.57B-$3.94B-$3.61B-$2.77B-$2.73B
Net Income
-$216.2M-$255.9M-$384.7M-$514.0M-$747.1M$12.20B$8.36B-$4.71B-$3.56B-$2.82B-$2.79B
EPS (Diluted)
-3.79-0.72-1.17-1.55-1.9628.2920.10-12.34-9.27-7.26-7.09
EBITDA
-$208.7M-$235.3M-$412.1M-$477.1M-$703.6M$13.54B$9.95B-$3.28B-$3.39B-$2.55B-$2.46B
Shares Out. (M)
64.09376.00328.80330.80381.33431.00416.00382.00384.00389.00430.00

Balance Sheet

MetricTrend2016201720182019202020212022202320242025TTM
Cash & Equivalents
$50.1M$134.9M$658.4M$235.9M$2.62B$6.85B$3.21B$2.91B$1.93B$2.60B$1.20B
Short-Term Investments
$1.01B$621.2M$863.1M$867.1M$1.98B$3.88B$6.70B$5.70B$5.10B$3.20B$3.98B
Total Current Assets
$1.09B$783.2M$1.56B$1.13B$6.30B$16.07B$13.43B$10.32B$8.10B$6.54B$7.34B
Total Assets
$1.42B$1.08B$1.96B$1.59B$7.34B$24.67B$25.86B$18.43B$14.14B$12.34B$13.47B
Total Current Liabilities
$162.8M$191.5M$222.8M$143.1M$4.39B$9.13B$4.92B$3.02B$2.21B$1.99B$2.03B
Long-Term Debt
$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$1.24B$3.55B
Total Liabilities
$575.3M$459.2M$431.9M$414.6M$4.78B$10.52B$6.74B$4.57B$3.24B$3.69B$6.63B
Stockholders' Equity
$841.9M$625.3M$1.53B$1.17B$2.56B$14.14B$19.12B$13.85B$10.90B$8.65B$6.84B
Retained Earnings
-$365.7M-$621.9M-$1.01B-$1.50B-$2.24B$9.96B$18.32B$13.61B$10.04B$7.22B$5.26B

Cash Flow Statement

MetricTrend2016201720182019202020212022202320242025TTM
Operating Cash Flow
$66.7M-$331.5M-$330.9M-$459.0M$2.03B$13.62B$4.98B-$3.12B-$3.00B-$1.87B-$1.76B
Capital Expenditure
-$33.1M-$58.4M-$105.8M-$31.6M-$67.4M-$284.0M-$400.0M-$707.0M-$1.05B-$192.0M-$185.0M
Free Cash Flow
$33.6M-$389.9M-$436.6M-$490.5M$1.96B$13.34B$4.58B-$3.83B-$4.05B-$2.06B-$1.95B
Investing Cash Flow
-$648.6M$416.1M-$372.5M-$14.9M-$1.67B-$8.52B-$5.18B$4.21B$1.95B$1.95B-$1.51B
Financing Cash Flow
$472.9M$168.0K$1.23B$51.1M$2.03B-$873.0M-$3.45B-$1.38B$56.0M$593.0M$3.34B
Issuance of Stock
$0.00$212.0K$1.23B$47.3M$2.04B$124.0M$65.0M$46.0M$66.0M$35.0M$188.0M
Repurchase of Stock
$0.00$0.00-$8.2M$2.9M$0.00-$857.0M-$3.33B-$1.15B$0.00$0.00-$2.0M
Net Debt Issuance
$0.00$1.4M$9.5M$1.0M-$6.0M-$140.0M-$184.0M-$270.0M-$10.0M$539.0M$3.54B
Stock Based Comp.
$39.4M$40.1M$72.6M$81.1M$93.0M$142.0M$226.0M$305.0M$429.0M$483.0M$351.0M
Net Change in Cash
-$109.0M$84.8M$523.5M-$422.8M$2.39B$4.22B-$3.64B-$289.0M-$999.0M$668.0M$61.0M

Dilution Tracker

Shares Outstanding
399M
5-Year Share Growth
+2.0%
Stock Issuance (TTM)
$188.0M
MetricTrend2016201720182019202020212022202320242025TTM
Shares Out. (M)
64.09376.00328.80330.80381.33431.00416.00382.00384.00389.00430.00
Change vs Prior %
—486.6%-12.6%0.6%15.3%13.0%-3.5%-8.2%0.5%1.3%10.5%
Stock Issuance
$0.00$212.0K$1.23B$47.3M$2.04B$124.0M$65.0M$46.0M$66.0M$35.0M$188.0M
Stock Repurchase
$0.00$0.00-$8.2M$2.9M$0.00-$857.0M-$3.33B-$1.15B$0.00$0.00-$2.0M
Stock Based Comp.
$39.4M$40.1M$72.6M$81.1M$93.0M$142.0M$226.0M$305.0M$429.0M$483.0M$351.0M

Margins & Profitability

MetricTrend2016201720182019202020212022202320242025TTM
Gross Margin %
86.1%90.0%81.6%48.5%95.1%85.2%71.3%31.5%54.2%55.3%28.0%
Operating Margin %
-206.4%-130.9%-347.1%-906.4%-95.0%75.0%49.9%-61.9%-123.3%-158.1%-116.0%
Net Margin %
-199.5%-124.3%-284.8%-853.7%-93.0%68.8%44.3%-68.8%-111.3%-145.2%-110.5%
EBITDA Margin %
-192.5%-114.3%-305.1%-792.4%-87.6%76.3%52.7%-47.9%-106.1%-131.3%-97.2%
FCF Margin %
31.0%-189.4%-323.3%-814.7%243.9%75.2%24.3%-55.9%-126.8%-106.2%-77.2%
ROE %
-25.7%-40.9%-25.1%-43.8%-29.2%86.3%43.7%-34.0%-32.7%-32.6%-37.6%
ROA %
-15.3%-23.6%-19.6%-32.3%-10.2%49.5%32.3%-25.6%-25.2%-22.9%-20.7%
ROIC %
-17.8%-30.2%-27.0%-37.7%-25.6%77.5%38.9%-27.5%-32.5%-29.7%-25.6%
R&D / Revenue %
253.4%199.4%336.2%824.3%170.6%11.2%17.5%70.8%142.0%161.1%105.3%

Growth (Year over Year)

Fiscal years. Rising share count growth means dilution.

MetricTrend2016201720182019202020212022202320242025
Revenue
0.0%89.9%-34.4%-55.4%1234.3%2107.6%6.4%-63.7%-53.3%-39.2%
Gross Profit
0.0%98.6%-40.5%-73.5%2518.2%1878.4%-11.0%-84.0%-19.5%-38.0%
Operating Income
0.0%-20.4%-74.1%-16.4%-39.8%1842.3%-29.2%-145.0%6.9%22.1%
Net Income
0.0%-18.4%-50.3%-33.6%-45.3%1733.3%-31.5%-156.4%24.5%20.8%
EPS (Diluted)
0.0%81.0%-62.5%-32.5%-26.5%1543.4%-29.0%-161.4%24.9%21.7%
Operating Cash Flow
0.0%-596.7%0.2%-38.7%541.6%571.9%-63.4%-162.6%3.7%37.6%
Free Cash Flow
0.0%-1260.7%-12.0%-12.3%499.5%580.6%-65.6%-183.5%-6.0%49.1%
R&D Expense
0.0%49.4%10.6%9.3%176.1%45.3%65.5%47.0%-6.2%-31.1%
SG&A Expense
0.0%12.7%45.6%16.3%71.7%201.2%99.6%36.8%-24.2%-13.3%
Total Assets
0.0%-23.5%80.9%-19.0%361.6%236.2%4.8%-28.7%-23.2%-12.8%
Book Value / Share
0.0%-87.3%179.8%-23.7%89.1%422.6%38.3%-25.3%-21.7%-21.7%
Debt
0.0%25.5%113.5%295.2%79.1%286.5%31.0%3.6%-39.9%156.5%
Diluted Shares
0.0%486.6%-12.6%0.6%15.3%13.0%-3.5%-8.2%0.5%1.3%

Valuation

P/E (TTM)At Loss
P/S40.19
10Y Low / Med / High3.75 / 11.00 / 107.47
P/B14.91
10Y Low / Med / High1.33 / 3.70 / 15.56
EV/EBITDAAt Loss
EV/Revenue41.37
10Y Low / Med / High3.64 / 10.65 / 105.75
P/FCFAt Loss
10Y Low / Med / High7.68 / 20.33 / 35.49

Intrinsic Value Models (per share)

Tangible Book / Share
$17.05
Net Current Assets / Share
$1.79
Cash / Share
$12.90
MetricTrend2016201720182019202020212022202320242025TTM
P/E Ratio
-4.91-25.83-13.05-12.62-53.308.388.45-8.06-4.49-4.06-35.95
P/S Ratio
11.0033.9837.17107.4749.595.773.755.554.995.9040.19
P/B Ratio
1.4211.183.285.5115.567.243.702.741.461.3314.91
EV/EBITDA
-5.53-29.21-10.67-13.35-53.237.126.91-11.06-4.36-4.23-42.55
EV/Revenue
10.6533.4032.55105.7546.625.443.645.304.625.5541.37

Analyst Estimates & Quality

Altman Z-Score
9.73
Safe
Piotroski F-Score
3
Weak

Forward Estimates (consensus)

MetricFY2026FY2027FY2028
Revenue$2.10B$2.43B$3.38B
Net Income-$3.27B-$1.77B-$1.06B
EPS$-8.42$-4.76$-2.85
# Analysts (EPS)151514

Revenue Segments

By Product

Segment202020212022202320242025
Messenger RNA (mRNA) Medicines$803.4M$18.47B$19.26B$6.85B——
Collaboration Arrangement————$12.0M—
Grant————$37.0M—
Product Sales————$4.52B—
COVID—————$1.81B
RSV—————$8.0M
Grant revenue—————$22.0M
Collaboration revenue—————$13.0M
Licensing and royalty revenue—————$11.0M
Stand-ready manufacturing revenue—————$80.0M

By Geography

Segment202020212022202320242025
Rest Of The World$38.9M$5.45B$7.30B$3.60B$810.0M$603.0M
UNITED STATES$764.5M$6.18B$5.15B$1.90B$1.78B$1.20B
Europe—$6.85B$6.82B$1.35B$598.0M$53.0M